Sanhueza H, Sivin I, Kumar S, Kessler M, Carrasco A, Yee J
Contraception. 1979 Jul;20(1):29-48. doi: 10.1016/0010-7824(79)90042-8.
To study the question of whether one brand of oral contraceptives may be as acceptable as another for use of publicly-assisted family planning programs, a double blind study of two well-known brands, Ovral and Norinyl, was undertaken in Costa Rica and Trinidad. The pills were randomly assigned to 1,200 women. Common side effects - nausea, dizziness, vomiting, headaches - were associated with both Norinyl and Ovral. Differences in event rates for these conditions were much more marked by country than by the pill used. Ovral was associated with increases in skin problems, notably chloasma, in Cost Rica. A higher percentage of women using Norinyl reported intermenstrual bleeding and spotting in both countries. In Costa Rica continuation rates for Norinyl were adversely affected by this. With these exceptions there appear to be no important differences between the brands that would affect their use in family planning programs.
为研究在公共资助的计划生育项目中,一种品牌的口服避孕药是否与另一种品牌一样可接受,在哥斯达黎加和特立尼达对两种知名品牌——奥炔诺孕酮片(Ovral)和复方炔诺酮片(Norinyl)进行了一项双盲研究。这些药片被随机分配给1200名女性。复方炔诺酮片和奥炔诺孕酮片都有常见的副作用,如恶心、头晕、呕吐、头痛。这些情况的发生率差异在不同国家间比在使用的药片间更为明显。在哥斯达黎加,奥炔诺孕酮片与皮肤问题增加有关,尤其是黄褐斑。在这两个国家,使用复方炔诺酮片的女性报告经间期出血和点滴出血的比例更高。在哥斯达黎加,复方炔诺酮片的持续使用率因此受到不利影响。除了这些情况外,这两种品牌之间似乎没有会影响其在计划生育项目中使用的重要差异。